Comparison

Anti-Mouse CD90.2 (Thy 1.2) - DyLight® 650

Item no. LEIN-C1696-200ug
Manufacturer Leinco Technologies
Amount 200 ug
Quantity options 100 ug 200 ug 50 ug
Category
Type Antibody Primary
Applications FC, FA
Clone 30-H12
Specific against Mouse (Murine, Mus musculus)
Host Rat
Citations 1. Ledbetter, J. and Herzenberg, L. (1979) Immunol. Rev. 47:63
2. Unkeless, J. C. (1979) J. Exp. Med. 150:580
NCBI 21838
ECLASS 10.1 32160702
ECLASS 11.0 32160702
UNSPSC 12352203
Shipping condition Cool pack
Available
Manufacturer - Applications
Quality Tested by Leinco FC The suggested concentration for this 30-H12 antibody for staining cells in flow cytometry is ≤ .25 μg per 106 cells in a volume of 100 μl or 100μl of whole blood. Titration of the reagent is recommended for optimal performance for each application.
Manufacturer - Category
Primary Monoclonal Antibodies>Surfacetag Mouse CD Markers
Manufacturer - Targets
CD90.2
Country of Origin
USA
Shipping Temperature
Next Day 2-8°C
Storage Conditions
This DyLight® 650 conjugate is stable when stored at 2-8°C. Do not freeze.
Product Description
CD90 is a 28-30 kD GPI-linked membrane glycoprotein and is part of the Ig superfamily. It interacts with CD45 in signal transduction. CD90 mediates adhesion of thymocytes to thymic stroma. It has been reported that CD90 binds with β2 and β3 integrins and is involved in the inhibition of hematopoietic stem cells proliferation and differentiation, as well as the regulation of cell adhesion and neurite outgrowth. It can be used as a marker for various stem cells, such as hematopoietic stem cells, and for the axonal processes of mature neurons. For use in FACS, CD90 is a popular surface marker for stem cells in combination with other markers such as CD34. There are two alleles for CD90 in mice that differ by one amino acid. The difference being that CD90.1 (Thy1.1) has an arginine and CD90.2 (Thy1.2) has a glutamine at position 108. CD90.2 is more prevalent and is expressed in most mice strains. CD90.1 is only expressed by a select few mice strains including AKR/J and PL strains. CD90.2 is a 25-35 kD GPI-anchored membrane glycoprotein. Like CD90, it is also in the Ig superfamily, interacts with CD45, and has involvement in signal transduction. The function of CD90.2 is thought to play roles in cognition, axon growth, T lymphocyte function, and apoptosis. CD90 acts as tumor suppressor for some tumors due to its action in upregulating thrombospondin, SPARC (osteonectin), and fibronectin. On the other hand, it has been suspected to aid in the spread of circulating melanoma cells. Regarding prostate cancer, CD90 has therapeutic potential for specific drug targeting due to its expression in cancer associated stroma, but not in normal stroma.
Background
CD90 is a 28-30 kD GPI-linked membrane glycoprotein and is part of the Ig superfamily. It interacts with CD45 in signal transduction. CD90 mediates adhesion of thymocytes to thymic stroma. It has been reported that CD90 binds with β2 and β3 integrins and is involved in the inhibition of hematopoietic stem cells proliferation and differentiation, as well as the regulation of cell adhesion and neurite outgrowth. It can be used as a marker for various stem cells, such as hematopoietic stem cells, and for the axonal processes of mature neurons. For use in FACS, CD90 is a popular surface marker for stem cells in combination with other markers such as CD34. There are two alleles for CD90 in mice that differ by one amino acid. The difference being that CD90.1 (Thy1.1) has an arginine and CD90.2 (Thy1.2) has a glutamine at position 108. CD90.2 is more prevalent and is expressed in most mice strains. CD90.1 is only expressed by a select few mice strains including AKR/J and PL strains. CD90.2 is a 25-35 kD GPI-anchored membrane glycoprotein. Like CD90, it is also in the Ig superfamily, interacts with CD45, and has involvement in signal transduction. The function of CD90.2 is thought to play roles in cognition, axon growth, T lymphocyte function, and apoptosis. CD90 acts as tumor suppressor for some tumors due to its action in upregulating thrombospondin, SPARC (osteonectin), and fibronectin. On the other hand, it has been suspected to aid in the spread of circulating melanoma cells. Regarding prostate cancer, CD90 has therapeutic potential for specific drug targeting due to its expression in cancer associated stroma, but not in normal stroma.
Additional Reported Applications For Relevant Conjugates
IHC (Frozen)
Costim
Depletion
For specific conjugates of this clone, review literature for suggested application details.
PubMed
CD90.2
Excitation Laser
Red Laser (652 nm)
Ligand/Receptor
CD45
Manufacturer - Research Area
Immunology
Manufacturer - Specificity
Clone 30-H12 recognizes the Thy-1.2 leukocyte marker.
RRID
AB_2828756
Concentration
0.2 mg/ml
Formulation
This DyLight® 650 conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Antigen Distribution
CD90.2 is present on hematopoietic stem cells and neurons, all thymocytes, peripheral T cells of the Thy-1.2 bearing mice.
Immunogen
Purified Recombinant Mouse CD90 (> 98%)
Additional Information
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Amount: 200 ug
Available: In stock
available

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question

Submit a bulk request

Questions about this Product?
 
Close